Modern Fertility

We're a women’s health company making personalized reproductive health information more accessible, earlier in life. We make the same laboratory tests that were previously confined to fertility clinics more accessible for women at home. By arming women with powerful information about their reproductive health, Modern Fertility is closing the fertility information gap and enabling women to own the decisions impacting their bodies and futures. We've raised $22 million from Forerunner Ventures, Maveron, Union Square Ventures, First Round Capital, #Angels and Y Combinator.

Modern Fertility is a women’s health company that offers an at-home fertility test designed for women who are not ready to have children immediately but want to understand their reproductive health proactively. Their flagship product is a $159 finger-prick blood test that estimates a woman’s egg reserve and hormone levels, previously only accessible through fertility clinics. By providing personalized reproductive health information earlier in life, Modern Fertility empowers women to make informed decisions about their fertility and future family planning. The company serves women seeking accessible, affordable, and clinically sound fertility insights, addressing the information gap in reproductive health. Since its founding in 2017, Modern Fertility has demonstrated strong growth momentum, culminating in its acquisition by digital health company Ro in 2021 for over $225 million, expanding its reach within women’s health services[1][4][5].

Founded by Afton Vechery and Carly Leahy, Modern Fertility emerged from Vechery’s background in healthcare-focused private equity and her passion for women’s health. After extensive research and shadowing fertility clinics, Vechery developed the idea to democratize fertility testing by making it accessible at home. Early traction came from clinical validation and partnerships that helped establish credibility, including publishing results with the American Academy for Obstetrics and Gynecology. The company’s growth was fueled by a clear mission to transform fertility care from reactive to proactive, supported by venture funding from top investors like Forerunner Ventures and Y Combinator[1][2][3].

Core Differentiators

• Product Differentiators: Modern Fertility offers a comprehensive, clinically validated fertility blood test that women can take at home with a simple finger prick, making fertility information accessible outside traditional clinics.
• User Experience: The test is affordable ($159) and easy to use, with results delivered through a digital platform that provides personalized insights and education.
• Community Ecosystem: The company builds a supportive community by normalizing fertility conversations and providing educational resources to close the fertility information gap.
• Clinical Credibility: Results and methodology have been published and presented to leading reproductive health organizations, ensuring trust and scientific rigor.
• Integration with Ro: Post-acquisition, Modern Fertility benefits from Ro’s vertically integrated telehealth platform, expanding services and improving care coordination for women’s health[1][4][5].

Role in the Broader Tech Landscape

Modern Fertility rides the growing femtech trend, which leverages technology to address women’s health needs that have historically been underfunded and underserved. The timing is critical as more women seek proactive, personalized health solutions and as telehealth adoption accelerates. Market forces such as increasing awareness of reproductive health, demand for convenient at-home testing, and the rise of digital health platforms favor Modern Fertility’s model. By making fertility testing accessible and affordable, the company influences the broader ecosystem by pushing healthcare toward prevention and personalization, while also highlighting gender bias in health research and funding[4][5].

Quick Take & Future Outlook

Looking ahead, Modern Fertility’s integration with Ro positions it to expand beyond fertility testing into a comprehensive women’s health vertical, potentially covering broader reproductive and preventive care. Trends shaping its journey include increased consumer demand for personalized health data, advances in telemedicine, and growing investment in femtech. As the company scales, it could redefine women’s healthcare by offering end-to-end support throughout reproductive life stages, driving better outcomes and lowering costs. Its influence is likely to grow as it helps shift the healthcare paradigm from reactive treatment to proactive, informed decision-making for women’s health[4][5].